摘要
目的探索CYP2C9和VKORC1基因多态性与川东北汉族肺栓塞患者华法林维持剂量的相关性。方法采用荧光染色原位杂交测序法,对60例川东北地区汉族肺栓塞患者CYP2C9、VKORC1基因型进行检测,对服用华法林的60例患者进行随访,评估CYP2C9、VKORC1对肺栓塞患者华法林维持剂量的影响。结果 60例服用华法林达维持剂量的患者中,CYP2C9 1075基因中AA型为85.0%,AC型为15.0%,CC型为0;VKORC1 1639基因中GG型为3.3%,AA型为83.3%,GA型为13.3%。各基因型所需的华法林剂量:CYP2C9 1075 AA基因型为(3.14±0.99) mg/d,AC基因型为(2.22±0.65) mg/d,VKORC1 1639 GG+GA基因型为(4.76±1.25) mg/d,AA基因型为(2.62±0.79) mg/d。结论 CYP2C9和VKORC1基因多态性会影响川东北地区汉族肺栓塞患者华法林的剂量,CYP2C9和VKORC1基因多态性的检测结果可为肺栓塞临床治疗调整华法林剂量提供依据。
Objective To explore the correlation between CYP2C9 and VKORC1 gene polymorphisms and warfarin maintenance dose in patients with pulmonary embolism in Northeast Sichuan. Methods The CYP2C9 and VKORC1 genotypes of 60 Han patients with pulmonary embolism in Northeast Sichuan were detected by fluorescence staining in situ hybridization and sequencing.60 patients taking warfarin were followed up to evaluate the effect of CYP2C9 and VKORC1 on the maintenance dose of warfarin in patients with pulmonary embolism. Results Among 60 patients taking warfarin maintenance dose,85. 0% of CYP2C91075 gene was AA type,15. 0% of AC type and 0 of CC type;In VKORC1 1639,GG,AA and GA were 3. 3%,83. 3% and13. 3%,respectively.The dose of warfarin for each genotype was (3. 14±0. 99) mg/d for CYP2C9 1075 AA, (2. 22±0. 65) mg/d for AC, (4. 76±1. 25) mg/d for VKORC1 1639 GG+GA,and (2. 62± 0. 79) mg/d for AA. Conclusion CYP2C9 and VKORC1 gene polymorphisms could affect the dose of warfarin in Han patients with pulmonary embolism in Northeast Sichuan. The results of CYP2C9 and VKORC1 gene polymorphism could provide a basis for adjusting the dose of warfarin in clinical treatment of pulmonary embolism.
作者
杨思芸
梁婧
苏强
朱丽莎
刘涛
Yang Siyun;Liang Jing;Su Qiang(Department of Pharmacy,Nanchong Central Hospital/Department of Cardiovascular Medicine,Individualized Drug Treatment of Nanchong Key Laboratory,Nanchong,Sichuan 637000,China)
出处
《四川医学》
CAS
2020年第6期557-560,共4页
Sichuan Medical Journal
基金
四川省科技计划项目(编号:2016JY0192)
南充市科技计划项目(编号:16YFZJ0030)。